Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pneumococcal Disease
Researchers' work from University of Alberta focuses on pneumococcal disease
October 22nd, 2008
According to recent research published in the journal Clinical Infectious Diseases, "The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for disease prevention in solid-organ transplant recipients, but it may have suboptimal immunogenicity. It may be possible to enhance immunogenicity by priming the recipient with the 7-valent pneumococcal conjugate vaccine (PCV7), followed by boosting with PPV23." "We randomized adult liver transplant recipients to receive either (1) PCV7 followed by a PPV23 booster 8 weeks later (the ''primed'' group) or (2) placebo followed by a standard single dose of PPV23 (the ''unprimed'' group). Quantitative and...
Source: Vaccine Weekly (2008-10-22)
|
